Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Bioverativ Inc buy stratec

Bioverativ Inc
Start price
€93.98
22.01.18 / 50%
Target price
€90.20
22.01.18
Performance (%)
-0.04%
End price
€93.94
22.01.18
Summary
This prediction ended on 22.01.18 with a price of €93.94. During the runtime of the prediction for Bioverativ Inc the price only changed by -0.04%. stratec has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Bioverativ Inc - - - -
iShares Core DAX® 0,22 % 1,49 % 3,58 % 50,28 %
iShares Nasdaq 100 6,05 % 16,19 % 39,14 % 107,46 %
iShares Nikkei 225® 5,72 % 11,69 % 50,96 % 76,35 %
iShares S&P 500 2,17 % 8,06 % 25,62 % 72,62 %

Comments by stratec for this prediction

In the thread Bioverativ Inc diskutieren
Prediction Buy
Perf. (%) -0.04%
Target price 90.200
Change
Ends at 22.01.18

stratec stimmt der Buy-Einschätzung von zeckenjoe zu


Sanofi nears $11.6B deal for Bioverativ
  • Sanofi (NYSE:SNY) is close to acquiring Bioverativ (NASDAQ:BIVV) for $105 a share, valuing the hemophilia drug maker - separated from Biogen (NASDAQ:BIIB) last year - at about $11.6B, according to multiple reports.
  • Sanofi
     expects the purchase to be immediately accretive to its EPS in the 2018
     full financial year, up to 5% accretive for the following year and
    achieve a ROIC in excess of the cost of capital before 2021.
  • Update: In a press release, Sanofi confirmed that it will acquire Bioverativ for $11.6B. BIVV is up 62% premarket on modest volume. SNY is down 3% on average volume.




stratec 
0
Report Share
22.01.18
Prediction Buy
Perf. (%) -0.04%
Target price 90.200
Change
Ends at 22.01.18

(Vom Mitglied beendet)

stratec 
0
Report Share
22.01.18